Age Differences in the Effects of Cannabis on Simulated Driving
ConditionCannabis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19-45
SponsorCentre for Addiction and Mental Health
About this trial
Epidemiological studies suggest that the use of cannabis is associated with an increase in the risk of motor vehicle collisions. It is also known that younger users may be at increased risk for motor vehicle collisions. Further, the frequency with which cannabis is used may be an important variable in determining the effects of cannabis on driving. The purpose of the present study will be to investigate the effects of cannabis on simulated driving in young as compared to middle-aged drivers. Half of the participants will be occasional users of cannabis and half will be frequent users of cannabis.
Eligibility criteria
Qualifiers
19-25 or 35-45 years of age;
Use of smoked cannabis at least once in the past 6 months.
Use of smoked or vaped cannabis primarily for recreational purposes on up to 1 day per week or on at least 6 days per week in the past 3 months;
Holds a class G or G2 Ontario driver's licence (or equivalent from another jurisdiction) for at least 12 months;
Disqualifiers
Use of cannabis primarily for therapeutic purposes, or equally for therapeutic and recreational purposes;
Diagnosis of medical condition that contraindicates use of cannabis determined by self-report as judged by the Principal Investigator and a study physician; this includes a history of hypersensitivity to cannabinoids smoke, respiratory disease and/or severe cardiovascular, cerebrovascular, renal or liver disease, and bleeding disorders. Smoking cannabis is not recommended for individuals with respiratory diseases, and they will be excluded;
Diagnosis of psychiatric condition that contraindicates use of cannabis determined by self-report or SCID-5;
Participants of childbearing potential: Pregnancy (point-of-care test) or breastfeeding;
Trial design
Treatments tested in this trial
- Cannabis
- Placebos
Treatment groups
128 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov